

CLINICAL LEADERSHIP EXECUTIVE OUTBRIEF	
Date of meeting	27th November 2020
Attendees	Group Triumvirates (Group Directors, Group Directors of Nursing and Group Directors of Operations), Director of Therapies and Executive Directors.
Apologies	Toby Lewis, Liam Kennedy, Bethan Downing
Key points of discussion relevant to the Board	<ul style="list-style-type: none"> • COVID-19 update • Results endorsement – progress in improving endorsement and update on processes underlying ordering in radiology and any potential unseen reports. • New structure to medicines management process in the Trust and how groups can be involved more in medicines management and safety culture • Patient safety role update around recruitment process and support from Groups for this
Positive highlights of note	<ul style="list-style-type: none"> • Gender equality paper on women at the top of the organisation with positive engagement from Groups
Matters of concern or key risks to escalate to the Board	<ul style="list-style-type: none"> • Results endorsement work still not leading to a significant change in performance so overall approach to which reports need endorsement to be reviewed
Matters presented for information or noting	<ul style="list-style-type: none"> • N/A
Decisions made	<ul style="list-style-type: none"> • Pharmacy reviewing how to increase pharmacist presence for ward based discussions on medicines safety, perhaps as part of safety huddles.

David Carruthers, Acting Chief Executive
Acting Chair of the Clinical Leadership Executive
For the meeting of the Trust Board scheduled for 3rd December 2020